Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic hepatitis C].

Hiromitsu Kumada1

  • 1Department of Hepatology, Toranomon Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 26, 2002
PubMed
Summary

Hepatitis C treatment with interferon alone shows low recovery rates. Combination therapy with interferon and ribavirin offers better outcomes for Hepatitis C virus (HCV) infection, especially for specific genotypes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals.

Oncology·2022
Same author

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.

Oncology·2022
Same author

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.

Journal of viral hepatitis·2022
Same author

A case of drug-induced acute liver failure caused by corticosteroids.

Clinical journal of gastroenterology·2022
Same author

Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan.

Hepatology research : the official journal of the Japan Society of Hepatology·2022
Same author

Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.

Science translational medicine·2022

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Context:

  • Hepatitis C virus (HCV) infection remains a significant global health concern.
  • Interferon monotherapy has demonstrated limited efficacy, with approximately 30% recovery rates.
  • Specific HCV genotypes, such as 1b and 2a, present treatment challenges.

Purpose:

  • To evaluate the effectiveness of combination therapy for Hepatitis C virus (HCV) infection.
  • To determine optimal treatment duration and strategies for managing difficult-to-treat HCV genotypes.
  • To explore preventative measures against hepatocellular carcinoma in HCV patients.

Summary:

  • Long-term combination therapy with interferon and ribavirin is more effective than interferon alone for HCV.
  • A one-year treatment duration is considered satisfactory for achieving better recovery rates.
  • Even with combination therapy, recovery for heavy HCV genotype 1b infections is around 50%, necessitating further research.

Impact:

  • Combination therapy with interferon and ribavirin is emerging as a mainstream treatment for HCV.
  • The findings underscore the need for novel therapeutic agents beyond ribavirin for HCV management.
  • Long-term, low-dose interferon may be considered for carcinoma prevention in HCV patients.

Related Experiment Videos